Delving into the Latest Updates on Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.. is a joint venture established through collaboration between Yipinhong Pharmaceutical Co., Ltd. and the globally recognized drug development innovator, Arthrosi Therapeutics.

Tags

Congenital Disorders

Immune System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

URAT1(Uric acid transporter 1)	1

The goal of this clinical trial is to evaluate the efficacy and safety of AR882 Capsules in patients with primary gout and hyperuricemia. The main questions it aims to answer are:
What is the efficacy of AR882 Capsules in reducing serum uric acid levels in patients with primary gout and hyperuricemia?
Researchers will compare AR882 Capsules with Febuxostat Tablets to see :
Phase II: To explore the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia, aiming to determine the dosing regimen for the Phase III study Phase III: To evaluate the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia.
Participants will:
Be randomly assigned to receive either AR882 Capsules or Febuxostat Tablets. Undergo regular assessments of serum uric acid levels. Report any adverse events or side effects experienced during the study.

Start Date22 Apr 2024

Sponsor / Collaborator

Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

CTR20241026

/ RecruitingPhase 2/3

评价AR882胶囊对比非布司他片治疗原发性痛风伴高尿酸血症患者的有效性和安全性的多中心、随机、双盲、平行对照、II/III期临床试验

[Translation] A multicenter, randomized, double-blind, parallel-controlled, phase II/III clinical trial to evaluate the efficacy and safety of AR882 capsules versus febuxostat tablets in the treatment of patients with primary gout and hyperuricemia

II期：（1）主要目的：探索AR882胶囊治疗原发性痛风伴高尿酸血症患者的有效性，以确定III期研究的给药方案。（2）次要目的：探索AR882胶囊在原发性痛风伴高尿酸血症患者中的安全性；基于群体药代动力学（PopPK）分析方法，探索AR882胶囊在原发性痛风伴高尿酸血症患者中的药代动力学（PK）特征；探索AR882和AR896的暴露与效应之间的关系。 III期：（1）主要目的：评价AR882胶囊治疗原发性痛风伴高尿酸血症患者的有效性（2）次要目的：评价AR882胶囊在原发性痛风伴高尿酸血症患者中的安全性；基于PopPK分析方法，探索AR882胶囊在原发性痛风伴高尿酸血症患者中的PK特征；探索AR882和AR896的暴露与效应之间的关系

[Translation]

Phase II: (1) Primary objective: To explore the efficacy of AR882 capsules in the treatment of patients with primary gout and hyperuricemia, so as to determine the dosing regimen for Phase III studies. (2) Secondary objectives: To explore the safety of AR882 capsules in patients with primary gout and hyperuricemia; to explore the pharmacokinetic (PK) characteristics of AR882 capsules in patients with primary gout and hyperuricemia based on the population pharmacokinetic (PopPK) analysis method; to explore the relationship between exposure and effect of AR882 and AR896. Phase III: (1) Primary objective: To evaluate the efficacy of AR882 capsules in the treatment of patients with primary gout and hyperuricemia (2) Secondary objectives: To evaluate the safety of AR882 capsules in patients with primary gout and hyperuricemia; to explore the PK characteristics of AR882 capsules in patients with primary gout and hyperuricemia based on the PopPK analysis method; to explore the relationship between exposure and effect of AR882 and AR896

Start Date19 Apr 2024

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

[+1]

CTR20230736

/ CompletedPhase 1

AR882胶囊在健康受试者中的单中心、随机、开放、单剂量、双周期、双交叉食物影响研究

[Translation] A single-center, randomized, open-label, single-dose, two-period, double-crossover food effect study of AR882 capsules in healthy subjects

（1）主要目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）药代动力学的影响；（2）次要目的：评价广州瑞安博医药科技有限公司研制的AR882胶囊（规格：25 mg）在中国健康受试者中的安全性和耐受性；（3）探索性目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）的药效动力学的影响。

[Translation]

(1) Primary objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacokinetics of AR882 capsules (specification: 25 mg); (2) Secondary objective: To evaluate the safety and tolerability of AR882 capsules (specification: 25 mg) developed by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. in healthy Chinese subjects; (3) Exploratory objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacodynamics of AR882 capsules (specification: 25 mg).

Start Date23 Sep 2023

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Other

Login to view more data